Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer

Reuters

2025/09/29

<a href="https://laohu8.com/S/LSTA">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer

Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571338178"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571338178\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571338178?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571338178","market":"us","top_or_hot":-1,"title":"Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9FlkGt:1","article_id":"2571338178","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571338178","pubTimestamp":1759147242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma  cohort of its Phase 1/2a CENDIFOX trial . The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide , in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research  Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LSTA":"LISATA THERAPEUTICS INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Lisata Therapeutics宣布Certepetide治疗胰腺癌的CENDIFOX试验取得令人鼓舞的初步结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"LSTA":0.9},"content_text":"Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    \n\n        Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}